These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 17008860)

  • 21. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
    J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The DREAM model's effectiveness in health promotion of AIDS patients in Africa.
    Magnano San Lio M; Mancinelli S; Palombi L; Buonomo E; Altan AD; Germano P; Magid NA; Pesaresi A; Renzi E; Scarcella P; Zimba I; Marazzi MC
    Health Promot Int; 2009 Mar; 24(1):6-15. PubMed ID: 19171667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Horberg MA; Hurley LB; Klein DB; Follansbee SE; Quesenberry C; Flamm JA; Green GM; Luu T
    Arch Surg; 2006 Dec; 141(12):1238-45. PubMed ID: 17178967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Panleucogating as an accurate and affordable flow cytometric protocol to analyse lymphocyte subsets among HIV-positive patients on HAART treatment in Mozambique.
    Ceffa S; Erba F; Assane M; Coelho E; Calgaro M; Brando B
    J Biol Regul Homeost Agents; 2005; 19(3-4):169-75. PubMed ID: 16602633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Audiologic and vestibular findings in a sample of human immunodeficiency virus type-1-infected Mexican children under highly active antiretroviral therapy.
    Palacios GC; Montalvo MS; Fraire MI; Leon E; Alvarez MT; Solorzano F
    Int J Pediatr Otorhinolaryngol; 2008 Nov; 72(11):1671-81. PubMed ID: 18814921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
    Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
    AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D; Berenguer J; Bellón JM; Miralles P; Cosin J; de Quiros JC; Conde MS; Muñoz-Fernández MA; Resino S
    J Infect; 2008 Feb; 56(2):130-6. PubMed ID: 18192020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
    Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
    J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Highly active antiretroviral therapy in HIV sero-positive children. Disease progression by baseline clinical, immunological and virological status].
    Rodríguez de Schiavi MS; Scrigni A; García Arrigoni P; Bologna R; Barboni G; Redondo J; Nastri M; Mecikovsky D; Cantisano C; Moreno R; Siciliani D; Lencina M; Luedicke N; Rezzónico G; Torolla JL; López Papucci S; Luis M; Libonati C; Gamba L; Barbarysky J; Pérez Hernández E; Zlatkes R
    Arch Argent Pediatr; 2009 Jun; 107(3):212-20. PubMed ID: 19543629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implant-prosthetic treatment in HIV-infected patients receiving highly active antiretroviral therapy: report of cases.
    Strietzel FP; Rothe S; Reichart PA; Schmidt-Westhausen AM
    Int J Oral Maxillofac Implants; 2006; 21(6):951-6. PubMed ID: 17190306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique.
    Marazzi MC; Bartolo M; Emberti Gialloreti L; Germano P; Guidotti G; Liotta G; Magnano San Lio M; Mancinelli S; Modolo MA; Narciso P; Perno CF; Scarcella P; Tintisona G; Palombi L
    Health Educ Res; 2006 Feb; 21(1):34-42. PubMed ID: 15947022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of beneficiaries of free anti-retroviral drugs in Malawi: a community consensus process.
    Muula AS; Maseko FC
    AIDS Care; 2007 May; 19(5):653-7. PubMed ID: 17505926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementing OpenMRS for patient monitoring in an HIV/AIDS care and treatment program in rural Mozambique.
    Manders EJ; José E; Solis M; Burlison J; Nhampossa JL; Moon T
    Stud Health Technol Inform; 2010; 160(Pt 1):411-5. PubMed ID: 20841719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meeting the immense need for HAART in resource-poor settings.
    Bogaards JA; Goudsmit J
    J Antimicrob Chemother; 2003 Nov; 52(5):743-6. PubMed ID: 14563896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.